Article Sidebar

Submitted
Jan 30, 2023
Published
Aug 3, 2023
Download
Pdf
Statistic
Read Counter : 471 Download : 403

Downloads

Download data is not yet available.

Main Article Content

Abstract

Typhoid fever is an infectious disease among humans caused by the bacterium Salmonella typhi. With the high Multi-Drug Resistance (MDR) of Salmonella typhi, selecting the right antibiotic is a factor that must be considered in addition to cost constraints. Therefore, cost-effectiveness is needed. This study aims to determine the cost-effectiveness of typhoid fever patients using ceftriaxone and cefixime antibiotics. The data used are retrospective, and the sampling was done by purposive sampling. This study was conducted at Berkah Pandeglang Regional Hospital. Sample in this study, namely typhoid fever patients of the period 2020-2021, who meet the inclusion and exclusion criteria. In this study, 16 samples were obtained. The results of this study showed that the total average direct medical costs for the ceftriaxone group were IDR 78.632.500 In contrast, the cefixime group was IDR 75.527.300. The ACER value of typhoid fever patients who used Ceftriaxone + cefixime was IDR 91,646.27, Ceftriaxone was IDR 77,463.89, and cefixime was IDR 88,027.15. The patients with typhoid fever who used Ceftriaxone were more cost-effective than those who used Cefixime

Keywords

Typhoid Fever Ceftriaxone Cefixime Cost-Effectiveness Analysis

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References

  1. Agnes, A., Citraningtyas, G., & Sudewi, S. (2019). Analisis Efektivitas Biaya Pada Pasien Anak Demam Tifoid Di Rumah Sakit Bhayangkara Manado. Pharmacon, 8(4), 767. https://doi.org/10.35799/pha.8.2019.29351
  2. Ahyar, H., Maret, U. S., Andriani, H., Sukmana, D. J., Mada, U. G., Hardani, S.Pd., M. S., Nur Hikmatul Auliya, G. C. B., Helmina Andriani, M. S., Fardani, R. A., Ustiawaty, J., Utami, E. F., Sukmana, D. J., & Istiqomah, R. R. (2020). Buku Metode Penelitian Kualitatif & Kuantitatif (Issue March).
  3. Gunawan, D. O., Indriani, L., & Dewi, M. (2020). Evaluasi Pemberian Antibiotik Pada Pasien Demam Tifoid Di Instalasi Rawat Inap Rumah Sakit Azra Kota Bogor. FITOFARMAKA: Jurnal Ilmiah Farmasi, 10(1), 54–64. https://doi.org/10.33751/jf.v10i1.1938
  4. Hidayat, M. A. (2018). Cost-Effectiveness Analysis Penggunaan Antibiotik Untuk Pasien Rawat Inap Demam Tifoid Di Rsud Bangil Tahun 2016. UIN Maulana Malik Ibrohim.
  5. Indrayathi, P.A & Noviyanti, R. (2016). Cost of Illness (Beban Ekonomi Penyakit Dalam Pembangunan Kesehatan). Universitas Udayana, 2, 1–60.
  6. Jannah, N., Ihwan, M., & Tandah, R. (2017). Efektifitas Biaya Penggunaan Seftriakson Dan Sefiksim Pada Pasien Demam Tifoid Rawat Inap Di Rsu Anutapura Palu Periode 2015-2017. 5(1), 45–50.
  7. Khoiriyah, S. D., & Lestari, K. (2018). Review Artikel: Kajian Farmakoekonomi Yang Mendasari Pemilihan Pengobatan Di Indonesia. Farmaka, 2(2), 105–112. https://doi.org/10.24123/mpi.v2i2.1391
  8. Magfirah, A. (2019). Analisis Efektifitas Biaya Kloramfenikol dan Siprofloksasin Pada Pengobatan Tifoid di RSUD Datu Beru Kota Takengon Aceh Tengah. Serambi Saintia : Jurnal Sains Dan Aplikasi, 7(2), 84. https://doi.org/10.32672/jss.v7i2.1578
  9. Mustofa, F. L., Rafie, R., & Megamelina, B. (2020). Hubungan Faktor Determinan dengan Kejadian Demam Tifoid pada Pasien Rawat Inap di Rumah Sakit Pertamina Bintang Amin Tahun 2018. Jurnal Medika Malahayati, 4(13–29), 791–792.
  10. Pratiwi, I., Azis, S., Kusumastuti, E., & Kesehatan, B. (2018). Rasionalitas Penggunaan Antibiotik Ciprofloxacin pada Penderita Demam tifoid. Biomedical Journal of Indonesia : Jurnal Biomedik Fakultas Kedokteran Universitas Sriwijaya, 4(2), 46–51.
  11. Puspasari, H., Suryaningrat, D., & Rizky, M. (2020). Analisis Biaya Pengobatan Pasien Diagnosa Demam Tifoid di Instalasi Rawat Inap RSUD Dr Soedarso Pontianak Tahun 2018. Jurnal Farmasi Dan Ilmu Kefarmasian Indonesia, 7(1), 1. https://doi.org/10.20473/jfiki.v7i12020.1-6
  12. Tuloli, T. S. (2017). Cost-Effectiveness Analysis Terapi Antibiotik Seftriakson dan Sefotaksim Pada Pasien Tifoid di RSUD Dr. M.M Dunda Limboto. Jurnal Entropi, 12(1), 97–103.
  13. Yunita, W. C., Pramestutie, H. R., Illahi, R. K., & Achmad, A. (2018). Analisis Cost-Minimization Penggunaan Sefotaksim, Seftriakson dan Levofloksasin pada Pasien Demam Tifoid dengan Status Pembayaran Umum dan Jaminan Kesehatan Nasional : Penelitian dilaksanakan di Rumah Sakit Daerah Kanjuruhan Kepanjen. Pharmaceutical Journal of Indonesia, 4(1), 11–15.
  14. Yusransyah, Rhopi’ah, S., Herlinawati, A. Y., Mursyid, A., & Udin, B. (2023). Perbandingan Penggunaan Obat Antibiotik di Instalasi Rawat Inap dan Rawat Jalan RSUD DR. Adjidarmo Lebak Tahun 2021. 8(1), 17–24.
  15. Yusransyah, Y., Udin, B., Abdillah, M., Murdianto, Y., Soraya Uli, E., & Suryana, N. (2022). Analisis Efektivitas Biaya Pasien Covid-19 Menggunakan Terapi Oksigen Dan Remdesivir Di Rsud Kabupaten Tangerang. JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X, 14(1), 17–24. https://doi.org/10.35617/jfionline.v14i1.75